South Africa's Adcock eyes deals in Nigeria; Par Pharma to buy India's Edict;

@FiercePharma: Facebook: No more 'no comment' for pharma. News | Follow @FiercePharma

> Adcock Ingram, South Africa's second-biggest drugmaker, would consider an acquisition in Nigeria as part of its plan to enter Africa's most populous nation, its chief executive said. Report

> Generic drug developer Par Pharmaceutical said it will buy India's privately held Edict Pharmaceuticals for up to $37.6 million in cash. News

> Billionaire investor Carl Icahn reported the sale of 2.6 million shares in Biogen Idec since late April, reducing his stake in the drug maker to 5.6 percent. Story

> A study published jointly by the Journal of Oncology Practice and the American Journal of Managed Care finds that 10 percent of patients failed to fill new prescriptions for oral cancer drugs. Article

> Mylan started selling a generic version of Abbott Laboratories' anti-seizure treatment Depakote Sprinkles capsules. Report

> FDA sent manufacturing-related warning letters to Cephazone Pharma, Golden State Medical Supply and Ningbo Smart Pharmaceutical. Item

> Older doctors are more likely to recommend lifestyle changes for patients with heart disease risk factors, while younger doctors are more likely to prescribe medications, a new study finds. Story

Biotech News

@FierceBiotech:  Sanofi's Zerhouni drops biotech model in favor of "open innovation." Story | Follow @FierceBiotech

@JohnCFierce: Panel at BIO June 29 includes execs from AstraZeneca, Acorda, HGS and Sanofi. Follow @JohnCFierce

> Successes, failures mark 30 years of HIV/AIDS research. Report 

> Radius lands $91M, plans listing as it executes Ph3 osteoporosis drug trial. Article 

> Vertex victory triggers big HQ move as Biogen ponders the future. Story 

Biotech Research News

> Scientists find better mouse model for major depressive disorder. News 

> Scientists use stem cells to cook up a batch of astrocytes, the brain's workhorses. Item 

> Brain has protective proteins that make it stronger after attack. Article 

> Heart failure progression is in the PINK1 gene. Story

>  WHO decides not to decide on remaining smallpox stockpiles. Item 

Manufacturing News

> QbD process steps studied in regulatory pilot. Report

> Thieves target generics in Pfizer trailer heist. News

> Issa wants FDA speed on J&J rehab. Item

> FTC asked to consider drug supply in pharma rulings. Story

> Show product flow in plant design plans. Report

And Finally... Taking an acetaminophen tablet daily for at least five years reduces the risk of developing prostate cancer by 38 percent, researchers from the American Cancer Society reported. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.